DSIJ Mindshare

Lupin announces USFDA approval of supplemental new drug for treating Trichomoniasis

DSIJ Intelligence 0 968 Article rating: 5.0

Lupin Limited announced on Thursday that United States Food & Drug Administration (USFDA) has approved the company’s supplemental new drug application (sNDA) to expand the use of Solosec (Secnidazole) to include the treatment of Trichomoniasis in adults.

RSS
1345678910Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR